Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma
- 22 December 2020
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 536, 26-31
- https://doi.org/10.1016/j.bbrc.2020.12.048
Abstract
No abstract availableKeywords
Funding Information
- Konkuk University
This publication has 24 references indexed in Scilit:
- Isatuximab: First ApprovalDrugs, 2020
- The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic DiseasesFrontiers in Immunology, 2019
- The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple MyelomaClinical Cancer Research, 2019
- CD38 as an immunotherapeutic target in multiple myelomaExpert Opinion on Biological Therapy, 2018
- CD38 antibodies in multiple myeloma: back to the futureBlood, 2018
- Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaThe New England Journal of Medicine, 2016
- Daratumumab: First Global ApprovalDrugs, 2016
- Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaThe New England Journal of Medicine, 2015
- CD38 Is Expressed on Inflammatory Cells of the Intestine and Promotes Intestinal InflammationPLOS ONE, 2015
- CD38: a new paradigm in lymphocyte activation and signal transductionImmunological Reviews, 1998